A Third Us Company Gets Approval To Use Embryonic Stem Cells For Research

01.04.11 | Sarah Harnisch

A U.S. biotech company has won FDA approval to use embryonic stem cells in clinical trials for treating macular degeneration, a common cause of vision loss in people over 60.  It's the second time the company Advanced Cell Technology, or ACT, has won government approval to use the controversial stem cells in trials to treat blindness.  ACT won clearance in November to use the cells for trial treatments in patients suffering from progressive juvenile vision loss.  The latest move marks only the third ever attempt to use embryonic stem cell therapy in human trials.  The first was last year, when a company called Geron used the cells on a patient with a spinal cord injury.